Inactivation of tumor suppressor gene Clusterin leads to hyperactivation of TAK1-NF-κB signaling axis in lung cancer cells and denotes a therapeutic opportunity
Related Experiment Video
Updated: Dec 6, 2025
Zhipeng Chen1, Zhenzhen Fan1, Xiaowei Dou2
1Key Laboratory of Functional Protein Research of Guangdong Higher Education Institutes and MOE Key Laboratory of Tumor Molecular Biology, Institute of Life and Health Engineering, College of Life Science and Technology, Jinan University, Guangzhou 510632, China.
Abstract:
Purpose: Clinical success of precision medicine is severely limited by de novo or acquired drug resistance. It remains a clinically unmet need to treat these patients. Tumor suppressor genes (TSGs) play a critical role in tumorigenesis and impact the therapeutic effect of various treatments. Experimental Design: Using clinical data, in vitro cell line data and in vivo mouse model data, we revealed the tumor suppressive role of Clusterin in lung cancer. We also delineated the signaling cascade elicited by loss of function of CLU in NSCLC cells and tested precision medicine for CLU deficient lung cancers. Results:CLU is a potent and clinically relevant TSG in lung cancer. Mechanistically, CLU inhibits TGFBR1 to recruit TRAF6/TAB2/TAK1 complex and thus inhibits activation of TAK1- NF-κB signaling axis. Lung cancer cells with loss of function of CLU show exquisite sensitivity to TAK1 inhibitors. Importantly, we show that a significant portion of Kras mutation positive NSCLC patients are concurrently deficient of CLU and that TAK1 kinase inhibitor synergizes with existing drugs to treat this portion of lung cancers patients. Conclusions: Combinational treatment with TAK1 inhibitor and MEK1/2 inhibitor effectively shrank Kras mutation positive and CLU deficient NSCLC tumors. Moreover, we put forward a concept that loss of function of a TSG rewires signaling network and thereby creates an Achilles' heel in tumor cells which could be exploited in precision medicine.
Insights
Clusterin (CLU) acts as a tumor suppressor in lung cancer. Loss of CLU creates vulnerabilities that can be targeted with TAK1 inhibitors for precision medicine in non-small cell lung cancer (NSCLC).
Area of Science:
- Oncology
- Molecular Biology
- Precision Medicine
Background:
- Drug resistance limits precision medicine efficacy in cancer treatment.
- Tumor suppressor genes (TSGs) are crucial in tumorigenesis and influence treatment outcomes.
- Clusterin (CLU) function in lung cancer requires further elucidation.
Purpose of the Study:
- To investigate the tumor suppressive role of Clusterin (CLU) in lung cancer.
- To delineate the signaling pathways affected by CLU loss-of-function in non-small cell lung cancer (NSCLC).
- To explore precision medicine strategies for CLU-deficient lung cancers.
Main Methods:
- Analysis of clinical, in vitro cell line, and in vivo mouse model data.
- Delineation of the signaling cascade involving CLU, TGFBR1, TRAF6/TAB2/TAK1, and NF-κB.
- Testing of TAK1 inhibitors and combination therapies in CLU-deficient NSCLC models.
Main Results:
- CLU functions as a potent tumor suppressor gene in lung cancer.
- CLU loss activates TAK1-NF-κB signaling by inhibiting TGFBR1 recruitment of the TRAF6/TAB2/TAK1 complex.
- CLU-deficient lung cancer cells exhibit sensitivity to TAK1 inhibitors, particularly in Kras-mutated NSCLC.
Conclusions:
- Combinational therapy with TAK1 and MEK1/2 inhibitors effectively reduces tumor size in Kras-mutated, CLU-deficient NSCLC.
- Loss of TSG function can reprogram cellular signaling networks, creating therapeutic vulnerabilities.
- Targeting these reprogrammed pathways offers a novel precision medicine approach for resistant lung cancers.
Related Concept Videos
Loss of Tumor Suppressor Gene Functions
When the tumor suppressor genes develop mutations or are lost, cells start growing out of control, leading to cancer. However, a single functional copy of the tumor suppressor gene is enough for the cells to maintain their normal functions and cell...
NF-κB-dependent Signaling Pathway
NF-κB-dependent Signaling Mechanism
The...
The Intrinsic Apoptotic Pathway
Interactions Between Signaling Pathways
Convergence and divergence, and cross-talk between signaling pathways
Two distinct signaling pathways can converge on a single functional unit, which may either be a single protein or a complex of proteins. The response is either functionally distinct or synergistic between the two pathways but different from the response...
mTOR Signaling and Cancer Progression
The mTOR pathway or the...
Cancer-Critical Genes II: Tumor Suppressor Genes
When the function of certain critical genes, especially those involved in cell cycle regulation and cell growth signaling cascades, gets disrupted, it upsets the cell cycle progression. Such cells with unchecked cell cycles start proliferating uncontrollably and eventually develop into tumors.
Such genes that act...


